COG ACCL1931
| Clinical Trial Title | A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy |
| Trial Status | Open to Enrollment |
| Start Date | 08/14/2023 |
| Location | Randall Children's Hospital at Legacy Emanuel |
| Trial Type | Pediatric Cancer (Oncology) |
| Specific Condition | B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 B Acute Lymphoblastic Leukemia, BCR-ABL1-Like Lymphoblastic Lymphoma Mixed Phenotype Acute Leukemia T Acute Lymphoblastic Leukemia |
| Description | This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. |
| Eligibility Criteria | Eligible Patients
Please contact Legacy's Cancer and Blood Disorders at Randall Children's Hospital at Legacy Emanuel for additional study inclusion/exclusion information. |
| IRB Number | Central IRB |
| Notes | Study Details | NCT04293562 | A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Study Details | NCT05602194 | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | ClinicalTrials.gov |
| Principal Investigator | Jason Glover, MD |
| Contact Name | Cancer and Blood Disorders at Randall Children's Hospital at Legacy Emanuel |
| Contact Phone | 503-276-9300 |
| Contact Fax | 503-276-9351 |
| Contact E-Mail | childcanc@LHS.ORG |
